Premium
New trials suggest no significant benefit from adjunctive aspirin for schizophrenia
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30704
Subject(s) - aspirin , positive and negative syndrome scale , schizophrenia (object oriented programming) , medicine , placebo , adjunctive treatment , randomized controlled trial , meta analysis , negative symptom , psychiatry , psychosis , alternative medicine , pathology
Two new randomized, placebo‐controlled trials have found no significant improvement in symptoms of schizophrenia resulting from use of adjunctive aspirin. The studies were included in a meta‐analysis that found a small but not statistically significant effect of aspirin on scores on the Positive and Negative Syndrome Scale (PANSS).